EGFR and non-small cell lung carcinoma: The aims of this study were to describe baseline characteristics, survival, and subsequent treatment patterns for patients with advanced nonsquamous NSCLC with EGFR ex19del or L858R mutation who received pemetrexed plus platinum or other platinum-based combination regimen as the next line of therapy after front-line EGFR TKI therapy at US oncology practices.